Valuation: Orthocell Limited

Market Cap 203M 142M 125M 118M 107M 201M 13.58B 1.42B 546M 6.93B 531M 520M 22.31B P/E 2027 *
-14.9x
P/E 2028 * -37.3x
Enterprise Value 175M 122M 108M 102M 92.37M 173M 11.71B 1.22B 471M 5.98B 458M 448M 19.23B EV / Sales 2027 *
9.2x
EV / Sales 2028 * 4.69x
Free-Float
83.41%
Yield 2027 *
-
Yield 2028 * -
1 day+4.70%
1 week+1.30%
Current month+1.96%
1 month+1.96%
3 months+7.59%
6 months+7.59%
Current year-28.11%
1 week 0.74
Extreme 0.735
0.8
1 month 0.67
Extreme 0.67
0.8
Current year 0.67
Extreme 0.67
1.16
1 year 0.67
Extreme 0.67
1.6
3 years 0.32
Extreme 0.322
1.79
5 years 0.3
Extreme 0.3
1.79
10 years 0.1
Extreme 0.105
1.79
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 2006-03-20
Chief Executive Officer 60 2006-03-20
Director of Finance/CFO - 2025-07-31
Director TitleAgeSince
Director/Board Member 60 2006-03-20
Director/Board Member 60 2023-03-07
Chairman - 2023-05-31
Date Insider Type Main position Quantity % Market Cap. Importance
7/20/26 Buy

Chairman

15,430 0.0057%
7/17/26 Buy 11,573 0.0043%
7/17/26 Buy

Director

16,603 0.0061%
Change 5-day change 1-year change 3-year change Capi.($)
+4.03%+1.30%-44.88%+105.26% 142M
+0.15%+3.20%+47.09%+34.27% 251B
-0.54%+2.27%+21.53%-8.86% 160B
-0.63%+2.51%-6.16%+41.02% 147B
-0.52%-2.32%-54.78%-16.89% 63.93B
+1.44%-0.79%+14.11%+27.14% 50.05B
-0.10%+4.65%+41.44%+56.53% 49.4B
-0.05%+3.26%-15.24%-19.48% 48.94B
+0.07%+4.12%+53.15%+61.65% 43.52B
+0.04%+9.92%+196.07%+98.14% 41.06B
Average +0.46%+3.05%+25.23%+37.88% 85.43B
Weighted average by Cap. -0.12%+3.20%+27.17%+25.79%

Financials

2027 *2028 *
Net sales 19M 13.25M 11.7M 11.07M 10.04M 18.81M 1.27B 133M 51.16M 649M 49.76M 48.68M 2.09B 38M 26.5M 23.39M 22.13M 20.07M 37.63M 2.54B 265M 102M 1.3B 99.53M 97.36M 4.18B
Net income -13M -9.07M -8M -7.57M -6.87M -12.87M -870M -90.83M -35M -444M -34.05M -33.31M -1.43B -5.25M -3.66M -3.23M -3.06M -2.77M -5.2M -351M -36.68M -14.14M -179M -13.75M -13.45M -577M
Net Debt -28M -19.53M -17.24M -16.31M -14.79M -27.73M -1.87B -196M -75.4M -957M -73.33M -71.74M -3.08B -24.65M -17.19M -15.17M -14.36M -13.02M -24.41M -1.65B -172M -66.37M -842M -64.56M -63.16M -2.71B
Logo Orthocell Limited
Orthocell Limited is an Australia-based regenerative medicine company. The Company is focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Its portfolio of products includes Striate+, Remplir, and OrthoACI. Striate+ is an acellular resorbable collagen membrane used for guided bone and tissue regeneration in dental applications. Remplir is a collagen-based nerve wrap designed to support nerve repair surgery in peripheral nerve repair. OrthoACI, or Autologous Chondrocyte Implantation, offers treatment for symptomatic defects of the articulating cartilage of the joints. OrthoACI uses the patient’s own healthy cartilage cells called chondrocytes to assist the regeneration of damaged cartilage. The Company is engaged in the development of its tendon cell therapy in the United States. Its autologous tendon therapy is an advanced injectable cellular therapy for the treatment of chronic tendon injuries.
Employees
-
Date Price Change Volume
26-09-29 A$0.7750 +4.03% 232,122
26-09-29 A$0.7450 0.00% 31,816
26-09-28 A$0.7450 +0.68% 387,715
26-09-25 A$0.7400 -5.13% 347,259
26-09-24 A$0.7800 +1.30% 1,019,131
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.7450AUD
Average target price
1.140AUD
Spread / Average Target
+53.02%

Quarterly revenue - Rate of surprise